Updates on clinical management of chronic myeloid leukaemia (CML)
IMPORTANCE
In order to apply for CME credits, Omnihealth Practice will collect your professional details and participation results for the corresponding College/ CME Programmes Administrator.
PLEASE ENSURE YOUR ACCOUNT DETAILS ARE CORRECT, including full name, and registration number. Omnihealth Practice is not responsible for any failure on application due to error details provided by participant. Should you have any questions, please contact [email protected]
To receive a certificate, you must achieve a passing score as designated by the corresponding college/ CME Programmes Administrator. You may view or print the certificate from RECORD, but you cannot alter it.
All the CME accredited programmes on Omnihealth Practice Education Portal are approved for healthcare professionals in Hong Kong SAR ONLY.
CME released
Expired
Valid for credit through:
Expired
CME accredited by:
Hong Kong College of Community Medicine - 0.5
Hong Kong College of Emergency Medicine - 0.5
The Hong Kong College of Family Physicians - 1
Hong Kong College of Paediatricians - 1
The Hong Kong College of Pathologists - 0.5
Hong Kong College of Physicians - 0.5
Hong Kong College of Radiologists - 0.5
The College of Surgeons of Hong Kong - 0.5
About the programme
Over the past decade, treatment-free remission (TFR) has moved from the trial setting to routine clinical practice. With careful patient selection, frequent molecular monitoring, structured follow-up and high-quality laboratory support, 10-30% of chronic myeloid leukemia-chronic phase (CML-CP) patients can achieve TFR.
In this video, Dr. Carol Cheung, Associate Consultant in the Division of Haematology, Haematological Oncology, Medical Oncology and HSCT at the Queen Mary Hospital, described the guideline-recommended timing and criteria to stop tyrosine kinase inhibitors (TKIs) after achieving TFR, and suggested a treatment option that can overcome TKI resistance for patients who are refractory or intolerant to multiple lines of TKIs.
Dr. Carol Cheung
Associate Consultant,
The Division of Haematology,
Haematological Oncology,
Medical Oncology and Haemopoietic Stem Cell Transplantation,
Queen Mary Hospital
Disclaimer
This is an educational programme developed through unrestricted support from the medical community, for the purpose of continuing medical education only. The views expressed on this portal reflect the experience and/or opinion of the author(s) and are not necessarily those of editors, publisher and sponsor(s). Because of rapid advances in medicine, independent verification of clinical diagnoses, medical suitability and dosage should be made before treatment prescription. The appearance of advertisement, if any, has no influence on content or presentation and does not imply the endorsement of products by the publication, or its authors and editors.